IGAN1
MCID: IGN003
MIFTS: 49

Iga Nephropathy 1 (IGAN1)

Categories: Genetic diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Iga Nephropathy 1

MalaCards integrated aliases for Iga Nephropathy 1:

Name: Iga Nephropathy 1 56
Berger Disease 56 74 29 6
Iga Nephropathy, Susceptibility to, 1 56 29
Iga Nephropathy 73 36
Igan 56 73
Iga Nephropathy, Susceptibility to, Type 1 39
Iga Nephropathy, Susceptibility to 6
Iga Glomerulonephritis 71
Nephropathy, Iga Type 13
Nephritis, Iga Type 56
Nephropathy Iga 54
Igan1 56

Characteristics:

OMIM:

56
Inheritance:
?autosomal dominant

Miscellaneous:
histologic features overlap with henoch-schonlein purpura (hspn)
incidence 5-50 per million (children) and 10-40 per million (adults)


HPO:

31
iga nephropathy 1:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



External Ids:

OMIM 56 161950
OMIM Phenotypic Series 56 PS161950
KEGG 36 H01581
UMLS 71 C0017661

Summaries for Iga Nephropathy 1

OMIM : 56 End-stage renal disease (ESRD) is a major public health problem, affecting 1 in 1,000 individuals and with an annual death rate of 20% despite dialysis treatment. IgA nephropathy (IgAN) is the most common form of glomerulonephritis, a principal cause of ESRD worldwide, affecting up to 1.3% of the population. Kidneys of patients with IgA nephropathy show deposits of IgA-containing immune complexes with proliferation of the glomerular mesangium. Typical clinical features include onset before age 40 with hematuria and proteinuria, and episodes of gross hematuria following mucosal infections are common; 30% of patients develop progressive renal failure. Although not generally considered a hereditary disease, striking ethnic variation in prevalence (Julian et al., 1985; D'Amico, 1987) and familial clustering (Scolari et al., 1999), along with subclinical renal abnormalities among relatives of cases, suggest a genetic component (Gharavi et al., 2000). (161950)

MalaCards based summary : Iga Nephropathy 1, also known as berger disease, is related to malignant hypertension and crescentic glomerulonephritis. An important gene associated with Iga Nephropathy 1 is IGAN1 (IgA Nephropathy), and among its related pathways/superpathways is Nephrin/Neph1 signaling in the kidney podocyte. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are arthralgia and hypertension

KEGG : 36 Primary IgA nephropathy is an immune-complex-mediated glomerulonephritis defined immunohistologically by the presence of glomerular IgA deposits accompanied by a variety of histopathologic lesions. It is known to be the most prevalent primary chronic glomerular disease worldwide. Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. Since the features of IgA nephropathy identified by light microscopy are nonspecific, immunofluorescence or immunoperoxidase studies demonstrating a predominant deposition of IgA are essential to establish a definitive diagnosis of IgA nephropathy. Genetic factors undoubtedly influence the pathogenesis of IgA nephropathy. Genomewide association studies have identified common susceptibility loci in the absence of a priori mechanistic hypotheses.

UniProtKB/Swiss-Prot : 73 IgA nephropathy: Most common primary glomerulonephritis, which is partly due to aberrant or incomplete galactosylation of IgA1 molecules.

Wikipedia : 74 IgA nephropathy (IgAN), also known Berger's disease (/b??r'?e?/) (and variations), or synpharyngitic... more...

Related Diseases for Iga Nephropathy 1

Diseases in the Iga Nephropathy 1 family:

Iga Nephropathy 2 Iga Nephropathy 3

Diseases related to Iga Nephropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 515)
# Related Disease Score Top Affiliating Genes
1 malignant hypertension 30.6 AGTR1 ACE
2 crescentic glomerulonephritis 30.5 SCGB1A1 NPHS2
3 membranous nephropathy 30.3 NPHS2 NPHS1 CD79A ACE
4 lipoid nephrosis 30.2 SERPINB7 NPHS2 NPHS1 CD79A
5 syphilis 30.1 CD79A ACE
6 renal hypertension 30.1 NPHS1 AGTR1 ACE
7 hypertensive nephropathy 30.1 AGTR1 ACE
8 idiopathic nephrotic syndrome 30.0 NPHS2 ACE
9 microvascular complications of diabetes 3 30.0 SERPINB7 NPHS1 AGTR1 ACE
10 acute proliferative glomerulonephritis 29.9 NPHS2 NPHS1
11 glomerular disease 29.9 NPHS2 NPHS1 CD79A ACE
12 nephrotic syndrome, type 2 29.8 NPHS2 NPHS1
13 hypertensive encephalopathy 29.8 AGTR1 ACE
14 hypertensive retinopathy 29.8 AGTR1 ACE
15 nail-patella syndrome 29.6 NPHS2 NPHS1
16 pulmonary edema 29.6 SCGB1A1 AGTR1 ACE
17 nephrotic syndrome 29.6 NPHS2 NPHS1 ACE
18 nephrotic syndrome, type 1 29.5 NPHS2 NPHS1
19 membranoproliferative glomerulonephritis 29.4 NPHS1 CD79A
20 end stage renal failure 29.4 NPHS2 NPHS1 AGTR1 ACE
21 nephrosclerosis 29.3 NPHS2 NPHS1 AGTR1 ACE
22 focal segmental glomerulosclerosis 29.0 NPHS2 NPHS1 AGTR1 ACE
23 chronic kidney disease 28.6 SERPINB7 NPHS2 NPHS1 AGTR1 ACE
24 kidney disease 28.3 SERPINB7 NPHS2 NPHS1 CD79A AGTR1 ACE
25 glomerulonephritis 27.9 SCGB1A1 NPHS2 NPHS1 MASP1 CD79A AGTR1
26 iga glomerulonephritis 26.9 SERPINB7 NPHS2 NPHS1 MASP1 FCAR CD79A
27 iga nephropathy 3 12.9
28 iga nephropathy 2 12.6
29 hematuria, benign familial 11.4
30 loin pain hematuria syndrome 11.4
31 tonsillitis 10.8
32 systemic lupus erythematosus 10.6
33 acute kidney failure 10.6
34 rapidly progressive glomerulonephritis 10.5
35 spondyloarthropathy 1 10.5
36 microvascular complications of diabetes 4 10.5
37 microvascular complications of diabetes 6 10.5
38 microvascular complications of diabetes 7 10.5
39 inflammatory spondylopathy 10.5
40 spondylitis 10.5
41 proteasome-associated autoinflammatory syndrome 1 10.5
42 liver cirrhosis 10.4
43 crohn's disease 10.4
44 hyperuricemia 10.4
45 lupus erythematosus 10.4
46 interstitial nephritis 10.4
47 amyloidosis 10.4
48 hepatitis b 10.4
49 sarcoidosis 1 10.4
50 polycystic kidney disease 10.4

Graphical network of the top 20 diseases related to Iga Nephropathy 1:



Diseases related to Iga Nephropathy 1

Symptoms & Phenotypes for Iga Nephropathy 1

Human phenotypes related to Iga Nephropathy 1:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 arthralgia 31 occasional (7.5%) HP:0002829
2 hypertension 31 HP:0000822
3 proteinuria 31 HP:0000093
4 hematuria 31 HP:0000790
5 purpura 31 HP:0000979
6 stage 5 chronic kidney disease 31 HP:0003774
7 nephritis 31 HP:0000123
8 iga deposition in the glomerulus 31 HP:0000794

Symptoms via clinical synopsis from OMIM:

56
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
proteinuria
hematuria, macroscopic and microscopic

Immunology:
serum circulating immune complexes contain galactose-deficient iga1

Genitourinary Kidneys:
proteinuria
hematuria, microscopic
hematuria, macroscopic (seen in children and young adults coincident with mucosal infection)
galactose-deficient iga1 deposits in the glomerular mesangium, with or without igm and igg
glomerular crescents (rare), seen on biopsy
more
Skeletal:
arthralgia (in some patients)

Clinical features from OMIM:

161950

MGI Mouse Phenotypes related to Iga Nephropathy 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.17 ACE AGTR1 C1GALT1 CD79A NPHS1 NPHS2

Drugs & Therapeutics for Iga Nephropathy 1

Drugs for Iga Nephropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Probucol Approved, Investigational Phase 4 23288-49-5 4912
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
rituximab Approved Phase 4 174722-31-7 10201696
8
Losartan Approved Phase 4 114798-26-4 3961
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
11
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
17
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Azathioprine Approved Phase 4 446-86-6 2265
20
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
21
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
22
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
23
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
24
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
25
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
26
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
27 interferons Phase 4
28 Interferon-alpha Phase 4
29 Cassava Phase 4
30 Mitogens Phase 4
31 HIV Protease Inhibitors Phase 4
32
protease inhibitors Phase 4
33 Anticholesteremic Agents Phase 4
34 Anti-Infective Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Antimetabolites Phase 4
37 Lipid Regulating Agents Phase 4
38 Antioxidants Phase 4
39 Antiparasitic Agents Phase 4
40 Antiprotozoal Agents Phase 4
41 Antimalarials Phase 4
42 Vasoconstrictor Agents Phase 4
43 Antineoplastic Agents, Immunological Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Tripterygium Phase 4
46 Omega 3 Fatty Acid Phase 4
47 Proteasome Inhibitors Phase 4
48 Serine Proteinase Inhibitors Phase 4
49 Angiotensin-Converting Enzyme Inhibitors Phase 4
50 Methylprednisolone Acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
2 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
3 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
4 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
5 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
6 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
7 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
8 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
9 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
10 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
11 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
12 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
13 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
14 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
15 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
16 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
17 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
18 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
19 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
20 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
21 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
22 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
23 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Not yet recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
24 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
25 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
26 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
27 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
28 A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
29 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
30 A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Completed NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
31 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
32 An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Completed NCT02282930 Phase 3 ACTH (Acthar) Gel
33 Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
34 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
35 Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
36 Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial Completed NCT00437463 Phase 3 Ramipril
37 A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy Completed NCT02232776 Phase 3 Losartan
38 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
39 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) Recruiting NCT03608033 Phase 3
40 A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
41 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie Herbal Compound;Immunosuppressive Agents
42 A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy Recruiting NCT03762850 Phase 3 sparsentan;irbesartan
43 Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
44 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
45 A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
46 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
47 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Withdrawn NCT00599963 Phase 3 paricalcitol
48 Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
49 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Unknown status NCT02682407 Phase 2
50 A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy Completed NCT02112838 Phase 2 Fostamatinib 150 mg;Fostamatinib 100 mg;Placebo

Search NIH Clinical Center for Iga Nephropathy 1

Genetic Tests for Iga Nephropathy 1

Genetic tests related to Iga Nephropathy 1:

# Genetic test Affiliating Genes
1 Berger Disease 29
2 Iga Nephropathy, Susceptibility to, 1 29

Anatomical Context for Iga Nephropathy 1

MalaCards organs/tissues related to Iga Nephropathy 1:

40
Kidney, Liver, T Cells, Heart, Skin, B Cells, Lung

Publications for Iga Nephropathy 1

Articles related to Iga Nephropathy 1:

(show top 50) (show all 418)
# Title Authors PMID Year
1
Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients. 56 6
12740691 2003
2
Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. 56 6
11828340 2002
3
Association of the CD14 gene -159C polymorphism with progression of IgA nephropathy. 54 56
12566518 2003
4
Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. 54 56
10470078 1999
5
Familial clustering of IgA nephropathy: further evidence in an Italian population. 54 56
10213640 1999
6
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 54 56
9259580 1997
7
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 54 56
7593601 1995
8
IgA nephropathy. 56
23782179 2013
9
Genome-wide association study identifies susceptibility loci for IgA nephropathy. 56
21399633 2011
10
IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. 56
18172551 2008
11
Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. 56
17634434 2007
12
Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. 56
17186473 2006
13
Genetic studies of IgA nephropathy. 6
16282702 2006
14
Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. 56
15067315 2004
15
Peroxisome proliferator-activated receptor gamma C161T polymorphisms and survival of Japanese patients with immunoglobulin A nephropathy. 56
14616762 2003
16
Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. 56
12746403 2003
17
IgA nephropathy. 56
12213946 2002
18
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. 56
11532091 2001
19
Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. 56
11231363 2001
20
Polymorphism in promoter region of Fcalpha receptor gene in patients with IgA nephropathy. 56
11281451 2001
21
IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. 56
11062479 2000
22
Identification and characterization of the promoter for the gene encoding the human myeloid IgA Fc receptor (FcalphaR, CD89). 56
11003388 2000
23
Evidence for genetic factors in the development and progression of IgA nephropathy. 56
10792601 2000
24
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. 56
9264010 1997
25
Familial cases of Berger's disease and anaphylactoid purpura: more frequent than previously thought. 56
2757072 1989
26
IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? 56
3337116 1988
27
The commonest glomerulonephritis in the world: IgA nephropathy. 56
3329736 1987
28
A major gene model for the familial aggregation of plasma IgA concentration. 56
3480689 1987
29
Dietary gluten and primary IgA nephropathy. 56
3762637 1986
30
Low incidence of IgA nephropathy in blacks. 56
4087701 1985
31
Familial IgA nephropathy. Evidence of an inherited mechanism of disease. 56
3855328 1985
32
Immunoglobulin A nephropathy. Quantitative immunohistomorphometry of the tonsillar plasma cells evidences an inversion of the immunoglobulin A versus immunoglobulin G secreting cell balance. 56
6406547 1983
33
IgA nephropathy. Correlation of clinical and histologic features. 56
6218335 1983
34
Family study in IgA nephritis: the possible role of HLA antigens. 56
7404656 1980
35
Mesangial IgA glomerulonephritis in HLA-identical brothers. 56
428154 1979
36
IGA nephropathy in HLA-identical siblings. 56
734738 1978
37
Mesangial IgA glomerulonephritis and HLA antigens. 56
661897 1978
38
HLA-Bw35 and mesangial IgA glomerulonephritis. 56
643002 1978
39
IgA nephropathy. 56
4601708 1974
40
IgA glomerular deposits in renal disease. 56
4107073 1969
41
Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. 54 61
12538733 2003
42
Role of IgA in IgA nephropathy. 54 61
2184209 1990
43
A boy with IgA nephropathy complicated by tubulointerstitial nephritis and uveitis (TINU) syndrome. 61
24075025 2015
44
Clinicopathological analysis of 155 patients with persistent isolated hematuria. 61
25264882 2014
45
Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. 61
23269570 2013
46
Prevalence of nephropathies in children and adolescents and alterations in renal biopsies in Minas Gerais, Brazil, from 1996 to 2010. 61
22658343 2013
47
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. 61
21448451 2011
48
Indication criteria for tonsillectomy in IgA nephropathy patients. 61
21865688 2011
49
[Renal involvement in Behcet's disease]. 61
20517850 2010
50
Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients. 54
20031928 2010

Variations for Iga Nephropathy 1

ClinVar genetic disease variations for Iga Nephropathy 1:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PIGR NM_002644.4(PIGR):c.1739C>T (p.Ala580Val)SNV Uncertain significance 13526 rs291102 1:207106478-207106478 1:206933133-206933133
2 SELE NM_000450.2(SELE):c.1402C>T (p.His468Tyr)SNV Uncertain significance 16667 rs5368 1:169696946-169696946 1:169727805-169727805

Expression for Iga Nephropathy 1

Search GEO for disease gene expression data for Iga Nephropathy 1.

Pathways for Iga Nephropathy 1

Pathways related to Iga Nephropathy 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.04 NPHS2 NPHS1

GO Terms for Iga Nephropathy 1

Cellular components related to Iga Nephropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 slit diaphragm GO:0036057 8.62 NPHS2 NPHS1

Biological processes related to Iga Nephropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excretion GO:0007588 9.32 NPHS2 NPHS1
2 regulation of vasoconstriction GO:0019229 9.26 AGTR1 ACE
3 regulation of blood vessel diameter GO:0097746 9.16 AGTR1 ACE
4 kidney development GO:0001822 9.13 C1GALT1 AGTR1 ACE
5 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.62 AGTR1 ACE

Molecular functions related to Iga Nephropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Iga Nephropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....